{"title":"鲁拉西酮与QTc延长风险无关","authors":"H. Oral","doi":"10.22237/CRP/1536278400","DOIUrl":null,"url":null,"abstract":"A critical appraisal and clinical application of Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Scheizer E, Pikalov A, Loebel A. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placeboand olanzapinecontrolled study. Am J Psychiatry. 2011 Sep;168(9):957-67. doi: https://doi.org/10.1176/appi.ajp.2011.10060907.","PeriodicalId":10422,"journal":{"name":"Clinical Research In Practice: The Journal of Team Hippocrates","volume":"105 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lurasidone is not associated with risk of QTc prolongation\",\"authors\":\"H. Oral\",\"doi\":\"10.22237/CRP/1536278400\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A critical appraisal and clinical application of Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Scheizer E, Pikalov A, Loebel A. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placeboand olanzapinecontrolled study. Am J Psychiatry. 2011 Sep;168(9):957-67. doi: https://doi.org/10.1176/appi.ajp.2011.10060907.\",\"PeriodicalId\":10422,\"journal\":{\"name\":\"Clinical Research In Practice: The Journal of Team Hippocrates\",\"volume\":\"105 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-09-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Research In Practice: The Journal of Team Hippocrates\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22237/CRP/1536278400\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research In Practice: The Journal of Team Hippocrates","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22237/CRP/1536278400","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Scheizer E, Pikalov A, Loebel A.卢拉西酮治疗精神分裂症的临床评价及临床应用中华精神病学杂志。2011;18(9):957-67。doi: https://doi.org/10.1176/appi.ajp.2011.10060907。
Lurasidone is not associated with risk of QTc prolongation
A critical appraisal and clinical application of Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Scheizer E, Pikalov A, Loebel A. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placeboand olanzapinecontrolled study. Am J Psychiatry. 2011 Sep;168(9):957-67. doi: https://doi.org/10.1176/appi.ajp.2011.10060907.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
